Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Xeno Transplants's share price for the quarter that ended in Mar. 2008 was $0.11. Xeno Transplants's Shares Outstanding (EOP) for the quarter that ended in Mar. 2008 was 40.36 Mil. Therefore, Xeno Transplants's market cap for the quarter that ended in Mar. 2008 was $4.44 Mil.
Xeno Transplants's quarterly market cap
declined
from Sep. 2007 ($36.93 Mil) to Dec. 2007 ($22.20 Mil) and
declined
from Dec. 2007 ($22.20 Mil) to Mar. 2008 ($4.44 Mil).
Xeno Transplants's annual market cap
stayed the same
from Jun. 2005 ($0.00 Mil) to Jun. 2006 ($0.00 Mil) but then
increased
from Jun. 2006 ($0.00 Mil) to Jun. 2007 ($48.32 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Xeno Transplants's Enterprise Value for Today is $0.00 Mil.
Xeno Transplants (OTCPK:XENO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Xeno Transplants Market Cap Related Terms
Xeno Transplants Market Cap Historical Data
* Premium members only.
The historical data trend for Xeno Transplants's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xeno Transplants's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeno Transplants Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeno Transplants's Market Cap distribution charts can be found below:
* The bar in red indicates where Xeno Transplants's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Xeno Transplants's Market Cap for the fiscal year that ended in Jun. 2007 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeno Transplants (XENO) has a Market Cap of $0.00 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xeno Transplants and its competitors.
Is Xeno Transplants' Market Cap too high?
Xeno Transplants' current Market Cap is $0.00 Mil.
How does Xeno Transplants' Market Cap compare to PRTX and GWSN?
Xeno Transplants' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 114.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xeno Transplants and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeno Transplants's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeno Transplants stock overvalued right now?
Xeno Transplants (XENO) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Xeno Transplants (XENO), the current Market Cap is $0.00 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address143 Gardner Road, Brookline, MA, USA, 02445
Xeno Transplants Corp is a bio-technology research and development company, which intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XENO has been successfully added to your 